Untitled

Hooge, Ask de; Loo, Faj van de; Bennink, Miranda B.; Richards, Christopher D.; Arntz, OJ; Berg, WB van den

doi:10.1186/ar500

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, synovium STAT1 was shown to be strongly activated in RA [46]. However, according to other reports, STAT3 instead of STAT1 was described to play a critical role in this disease, since STAT1(-/-) mice resulted in exacerbation of the chronic joint inflammation and granuloma formation [48]. However, according to other reports, STAT3 instead of STAT1 was described to play a critical role in this disease, since STAT1(-/-) mice resulted in exacerbation of the chronic joint inflammation and granuloma formation [48].…”

Section: -Celiac Disease (Cd Gluten-sensitive Enteropathy) -Rheumatomentioning

confidence: 99%

STAT1 as a New Molecular Target of Anti-Inflammatory Treatment

Prati

Ciampa²,

Cavalieri³

et al. 2005

CMC

View full text Add to dashboard Cite

Cyclooxygenase (COX) is widely considered as the molecular target of non-steroid anti-inflammatory drugs (NSAIDs). However, due to the harmful side effect frequently observed following chronic use, the development of new anti-inflammatory agents is the matter of many studies. Signal transducers and activators of transcription (STAT) are a family of nuclear proteins mediating the action of a number of cytokines. Among them, STAT1 plays a critical role in the signal transduction pathway of interferon-gamma (IFN-gamma) and growth hormone. STAT1 cascade is one major signalling pathway converting the IFN-gamma signal into gene expression, such as inducible nitric oxide synthase (iNOS), COX, vascular cell adhesion molecules (VCAM) and intercellular cell adhesion molecules (ICAM), critically involved in different pathologies correlated to the inflammatory process. This review focuses the attention on an alternative approach to the development of novel drugs based on inhibition of STAT1 pathway. In this context, a growing interest has been focused on natural compounds. We have recently reported a several data indicating that green tea extract (GTE), St. John's Wort extract and epigallocatechin-3-gallate (EGCG) exhibit a specific and strong anti-STAT1 activity which is independent of their acclaimed strong anti-oxidant activity. More recently, GTE has been shown to protect heart damage from ischaemia/reperfusion in rats, suggesting that the protective effect of green tea might be correlated to its anti-STAT1 activity. The present review is aimed at providing data that STAT1 may potentially be claimed as a new molecular target of an anti-inflammatory treatment and that among natural compounds there are a number of anti-STAT1 substances.

show abstract

Section: -Celiac Disease (Cd Gluten-sensitive Enteropathy) -Rheumatomentioning

confidence: 99%

STAT1 as a New Molecular Target of Anti-Inflammatory Treatment

Prati

Ciampa²,

Cavalieri³

et al. 2005

CMC

View full text Add to dashboard Cite

show abstract

“…Epidemiological studies show that the IL‐6 level is positively correlated with the development of OA 19–21 . Experiment evidence from the mouse model indicates that the IL‐6 gene knockout mice have a more severe spontaneous OA compared with the control 22 . Mitochondrial dysfunction is associated with almost all aging‐related diseases, including OA 23,24 .…”

Section: Pathogenesis Of Oa and Clinical Treatmentmentioning

confidence: 99%

Functional biomaterials for osteoarthritis treatment: From research to application

et al. 2022

View full text Add to dashboard Cite

Osteoarthritis (OA) is a common disease that endangers millions of middle‐aged and elderly people worldwide. Researchers from different fields have made great efforts and achieved remarkable progress in the pathogenesis and treatment of OA. However, there is still no cure for OA. In this review, we discuss the pathogenesis of OA and summarize the current clinical therapies. Moreover, we introduce various natural and synthetic biomaterials for drug release, cartilage transplantation, and joint lubricant during the OA treatment. We also present our perspectives and insights on OA treatment in the future. We hope that this review will foster communication and collaboration among biological, clinical, and biomaterial researchers, paving the way for OA therapeutic breakthroughs.

show abstract

“…Such changes infer that IL-6 may affect systemic events such as high fever, autoantibody production and expression of acute phase reactants. Indeed, a series of in vivo studies using models of experimental arthritis have now endorsed roles of IL-6 in joint destruction, leukocyte recruitment, apoptosis, and T-cell activation [3,4,104,[116][117][118][119][120]. Indeed, a series of in vivo studies using models of experimental arthritis have now endorsed roles of IL-6 in joint destruction, leukocyte recruitment, apoptosis, and T-cell activation [3,4,104,[116][117][118][119][120].…”

Section: Il-6 As a Therapeutic Targetmentioning

confidence: 99%

Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression

Jones¹,

Jones²,

Williams³

et al. 2008

IEMAMC

View full text Add to dashboard Cite

The humanized anti-interleukin (IL)-6 receptor antibody Tocilizumab is currently in Phase III clinical trials for use in autoimmune conditions such as rheumatoid arthritis and Crohn's disease. However do we fully appreciate the regulation of IL-6 responses in vivo, and understand the wider implications of IL-6 bioactivity in general physiology and inflammation? In the context of this review we will explore how IL-6 affects arthritis progression, and discuss the inflammatory mechanism governing IL-6 responsiveness. Specific attention will be given to the role of the soluble IL-6 receptor and we will discuss the merit of selectively targeting this soluble receptor as an alternative therapeutic strategy for clinically blocking IL-6 involvement in disease.

show abstract

Untitled

Abstract: Comparison of the features of arthroscopic synovial biopsies with biopsy samples obtained at surgery

Cited by 3 publications

References 0 publications

STAT1 as a New Molecular Target of Anti-Inflammatory Treatment

STAT1 as a New Molecular Target of Anti-Inflammatory Treatment

Functional biomaterials for osteoarthritis treatment: From research to application

Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression

Contact Info

Product

Resources

About